The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...

A clinical trial co-led by Yale Urology showed high resolution micro-ultrasound is an effective tool for guiding prostate ...

A University of Alberta-led international study could change the standard method of diagnosis for prostate cancer patients, ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

Prostate cancer is the second-leading cause of cancer deaths in American men. Further, non-Hispanic Blacks have a higher ...

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...

In the U.S., the accuracy and sensitivity of PSMA-PET imaging means it has become the standard of care for prostate cancer imaging after initial diagnosis and biochemical recurrence 2. However, only a ...

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Imaging Prior to Initial Definitive or Suspected Recurrence Therapy The ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...